Meet Dr. Jeffrey Zonder - Hematologic Malignancies | Karmanos Cancer Institute
Updates from American Society of Hematology 2022 Meeting with Dr. Jeffrey Zonder, M.D. | CAR-T Cells
Treatment Landscape for Relapsed and Refractory Multiple Myeloma
Dr. Jeffrey Zonder Zoom discussion 5 13 20
Dr. Jeffrey Zonder, May 8, 2024 - Ask the Doctor Discussion
ASH 01 Jeffrey Zonder
"Progress in Amyloidosis Research: Where Are We Now?"
Safety of the Bispecific Antibody, REGN5458, in Multiple Myeloma Patients
MCRT Detroit 2017: Jeffrey Zonder, MD on Combo Regimens, Transplants, and Clinical Trials
Multiple Myeloma cancer patient and his oncologist prepare for the hike of a lifetime
The Changing Paradigm of Amyloidosis Treatment
Dr. Deol on the Nuances of Utilizing CAR T-Cell Therapy in Lymphoma and Leukemia
Treatment of Elderly Patients With Multiple Myeloma
Innovative Therapy in Multiple Myeloma: Monoclonal Antibodies and BCMA and Non-BCMA Options
Examining strategies to tailor multiple myeloma immunotherapy
MCRT Detroit 2017: Myeloma Expert Panel Q&A (Morning)
Dr Zonder discussion 4 28 21
Debate: Patients with Early Relapsed MM should Receive 3-Drug Salvage Therapy
Pomalidomide and HDAC Inhibitors in Multiple Myeloma
Ask the Doctor Multiple Myeloma Discussion with Dr Zonder 6 1 22
